Kupando Announces First Patient Dosed in Phase 1 Clinical Study of Lead Candidate KUP101 in Advanced Solid Tumors
- Milestone marks Kupando’s evolution from a research-focused organization to a clinical-stage biopharmaceutical company
- Phase 1 trial evaluates KUP101, a differentiated dual Toll-Like Receptor (TLR) 4/7 agonist designed to harness innate immunity…